Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab Plus Ipilimumab for MPNST
NCT04465643Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jun 2021
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab and ipilimumab in malignant peripheral nerve sheath tumor (MPNST) and neurofibromatosis type 1 (NF1), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Safety of combination nivolumab and ipilimumab up to 2 years, Feasibility of combination nivolumab and ipilimumab up to 2 years and 2 more. Started Jun 2021; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
malignant peripheral nerve sheath tumor (MPNST)neurofibromatosis type 1 (NF1)
Beyond the preview
Go deeper on NCT04465643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04465643.